S. Yu. Romanova

S. Yu. Romanova

Auto-generated profile, based on publicly available information

S. Yu. Romanova

Center for the prevention and control of AIDS and infectious diseases

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2018 in Journal Infectology
Verified
Journal Article
Open access
PDF file
NDN. V. Dunaeva
N. V. Dunaeva
EKE. Yu. Kolpashchikova
E. Yu. Kolpashchikova
SRS. Yu. Romanova
S. Yu. Romanova
SKS. N. Kizhlo
S. N. Kizhlo
SLS. V. Lapin
S. V. Lapin
DGD. A. Gusev
D. A. Gusev
The aim of the study was to evaluate clinical, immunologic and anti-viral efficacy of antiviral therapy (АVT) withdrugs of the direct antiviral action (DAA) of the chronic hepatitis C (CHC) complicated with secondary mixed cryoglobulinemia in small cohort of patients. Patients and methods: The cohort consisted of 12 patients with CHC (without signs of a coinfection of HIV, a hepatitis B virus) complicated with mixed cryoglobulinemia (criocrit more than 5% and presence of cryoglobulinemia-related symptoms). Standard DAA based therapy was indicated in all patients: 2 cases daclatasvir and asunaprevir, 3 cases daclatasvir and sofosbuvir and 7 cases Dasabuvir;Ombitasvir+Paritaprevir+Ritonavir. Results: Anti-viral response at 12 and 24 weeks was found in 91,6% (11/12) treated patients. In one case (on the daclatasvir and asunaprevir) resistance to both drugs developed. Clinical response was confirmed in 83% – 10/12 (25% – the complete response, 58% – the partial response). Despite of anti-viral response kidney damage persisted in 2 patients without apparent improvement. There was one lethal outcome at 25th week since the beginning of treatment because of bilateral pneumonia and thromboembolism in patient with kidney involvement treated with steroids and cytostatics. In 25% of patients total elimination of cryoglobulins was confirmed by the end of AVT and in 75% dramatic decrease of criocrit was found. Conclusion: We confirmed good virologic, clinical and immunologic response and safety of AVT with DDA in patients with HCV induced crioglobulinemia, especially when using schemes with a high genetic barrier (daclatasvir and sofosbuvir, Dasabuvir;Ombitasvir+Paritaprevir+Ritonavir).

21 March 2020 in Journal Infectology
Verified
Journal Article
Open access
PDF file
NDN. V. Dunaeva
N. V. Dunaeva
MCM. A. Chirskaya
M. A. Chirskaya
EKE. Yu. Kolpashchikova
E. Yu. Kolpashchikova
SRS. Yu. Romanova
S. Yu. Romanova
SLS. V. Lapin
S. V. Lapin
DGD. A. Gusev
D. A. Gusev
В статье демонстрируется случай хронического гепатита С 1b генотипа с фиброзом 3 степени по Metavir, осложнённый развитием смешанной криоглобулинемии III типа, криоглобулинемическим васкулитом с поражением сосудов кожи (геморрагический васкулит), печени (альтеративно-пролиферативный васкулит). Назначение режима даклатасвир + асунапревир оказалось вирусологически неудачным: на фоне вирусологического прорыва были выявлены мутации D168E и L31V. Повторный курс противовирусной терапии комбинацией Гразопревир+Элбасвир в сочетании с софосбувиром привел к достижению устойчивого вирусологического ответа, частичным иммунологической и клинической ремиссиям.

17 January 2023 in Siberian Journal of Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
NDN. V. Dunaeva
N. V. Dunaeva
SRS. Yu. Romanova
S. Yu. Romanova
IDI. A. Dubina
I. A. Dubina
SLSergey V. Lapin
Sergey V. Lapin
VRVadim Rassokhin
Vadim Rassokhin
DGD. A. Gusev
D. A. Gusev
Introduction. Several viruses including hepatitis C virus (HCV) and human immunodeficiency virus (HIV) can induce vasculitis.Aim. We aimed to study the incidence, risk factors, and severity of skin vasculitis in patients with HCV and HCV/HIV coinfection.Patients and Methods. The study group included 331 patients (254 patients with HCV and 77 patients with HCV/HIV coinfection) referred to a specialized hepatology center for antiviral therapy of HCV infection.Results. Skin vasculitis was found in 21% (95% CI: 17–25%) of cases, n = 69/331. Skin vasculitis was observed in in 20% of patients infected with HCV (95% CI: 15–25%) and in 25% of HIV/HCV co-infected patients (95% CI; 16–35%), χ2 = 0,892, р = 0,345. Most patients with vasculitis infected with HCV had cryoglobulinemia (94%, n = 47/50), meanwhile, in HIV/HCV co-infected patients, cryoglobulinemia was found in 63% cases (n = 12/19), χ2 = 10.568, р = 0.001. Multiple regression analysis showed that skin vasculitis was related with cryoglobulinemia (OR = 6,928, 95% CI: 3.245–14.790, р < 0.001), liver cirrhosis (OR = 2.015, 95% CI: 1.062–3.824, р = 0.032), duration of overt HCV infection (OR = 1.057, 95% CI: 1.021–1.094, р = 0.002), patients age (OR = 1.029, 95% CI: 1.002–1.057, р = 0.033) and inversely related with plasma alanine transaminase (OR 0.433, 95% CI: 0.229–0.820, р = 0.010). The statistical model was normalized for gender, HIV-positivity and bilirubin levels, and regression equation constant was 4.398 (p < 0.001). The intensity of skin rashes was comparable in HCV infected and HCV/HIV co-infected patients (χ2 = 6.741, р = 0.081), and was highly correlated with cryoglobulin levels both in HCV infected (r = 0.788, p < 0.001), and HCV/HIV co-infected patients (r = 0.909, p = 0.001).Conclusion. Skin vasculitis was found in 20–25% of cases among patients with HCV infection and HCV/HIV co-infection. Cryoglobulinemia was the main factor associated with skin vasculitis, and severity of skin lesions was closely related with cryoglobulin levels.

24 June 2025 in Journal Infectology
Verified
Journal Article
Open access
PDF file
EYE. B. Yastrebova
E. B. Yastrebova
ATA. G. Trishina
A. G. Trishina
SRS. Yu. Romanova
S. Yu. Romanova
TVT. N. Vinogradova
T. N. Vinogradova
The hepatitis B virus (HBV) and the disease it causes have been actively studied for over 50 years. Recent estimates provided by the World Health Organization indicate that approximately 1 in 22 (4.5%) individuals with chronic hepatitis B have antibodies to the hepatitis D virus (HDV). The exact global prevalence of hepatitis D remains unclear due to differences in the sensitivity and specificity of diagnostic tests and the lack of standardized testing systems. In Russia, patients with hepatitis D are not subject to mandatory registration, and the routes of transmission are similar to those of hepatitis B. The disease is often diagnosed at a late stage (e.g., liver cirrhosis) due to the lack of widespread targeted screening for HDV antibodies among HBsAg-positive patients; about two-thirds of patients are unaware of their infection status. The study of socio-epidemiological and clinical-laboratory characteristics of HIV-positive patients co-infected with chronic hepatitis B and delta agent is of significant scientific and practical interest.The aim of this study was to conduct a comparative analysis of socio-epidemiological and clinical-laboratory features of HIV-positive patients with chronic hepatitis B and delta agent compared to patients without HIV infection. Materials and Methods. The study included 50 patients under observation at the city AIDS center, of whom 24 were diagnosed with HIV infection and chronic hepatitis B+D (Group 1), and 26 had chronic hepatitis B+D without HIV infection (Group 2). The mean age of the patients was 46.7±0.5 years, with 34 males (68.0%) and 16 females (32.0%).Results and Discussion. The “social profile” of HIV-positive patients with chronic hepatitis B+D is characterized as follows: these individuals are typically intravenous drug users, lack higher education, are unemployed, not in formal marriages, and have an HIV infection duration of more than 8 years, often with stage 4A HIV infection according to the Russian classification. All patients in this group were receiving antiretroviral therapy, and the vast majority were also on antiviral therapy for chronic hepatitis. Conclusion. Thus, HIV-positive patients with chronic hepatitis B+D significantly differ from those with chronic hepatitis B+D alone in terms of infection routes, education level, marital status, disease duration, aminotransferase levels, and hematological abnormalities. In both groups, severe liver fibrosis (F3-F4) predominated, accounting for a total of 70%. Antiviral therapy for chronic hepatitis B+D using bulevirtide represents a promising direction for the elimination of HBV and HDV and requires further study and analysis.